The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wang, Haitao ^a   Wang, Rikang ^a   Thrimawithana, Thilini ^b   Little, Peter J ^b   Xu, Jiangping ^c   Feng, Zhong Ping ^d   Zheng, Wenhua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b RMIT UNIVERSITY   (Australia)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; EYE DROPS;

DRUG TARGETING; GLAUCOMA; HUMAN; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PROTEIN EXPRESSION; PROTEIN INTERACTION; RETINA; RETINA DEGENERATION; RETINA GANGLION CELL; REVIEW; SIGNAL TRANSDUCTION; VISUAL CORTEX; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

GLAUCOMA; HUMANS; MOLECULAR TARGETED THERAPY; NERVE GROWTH FACTOR; OPHTHALMIC SOLUTIONS; SIGNAL TRANSDUCTION;

EID: 84930883811     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/759473     Document Type: Review

References (103)

1. M. V. Boland, A.-M. Ervin, D. S. Friedman et al., "Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U. S. preventive services task force, " Annals of Internal Medicine, vol. 158, no. 4, pp. 271-279, 2013.
2. L. Feng, Y. Zhao, M. Yoshida et al., "Sustained ocular hypertension induces dendritic degeneration of mouse retinal ganglion cells that depends on cell type and location, " Investigative Ophthalmology & Visual Science, vol. 54, no. 2, pp. 1106-1117, 2013.
3. R. H. Foxton, A. Finkelstein, S. Vijay et al., "VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma, " The American Journal of Pathology, vol. 182, no. 4, pp. 1379-1390, 2013.
4. M. V. Sofroniew, C. L. Howe, andW. C. Mobley, "Nerve growth factor signaling, neuroprotection, and neural repair, " Annual Review of Neuroscience, vol. 24, pp. 1217-1281, 2001.
5. S. J. Allen, J. J. Watson, D. K. Shoemark, N. U. Barua, and N. K. Patel, "GDNF, NGF and BDNF as therapeutic options for neurodegeneration, " Pharmacology and Therapeutics, vol. 138, no. 2, pp. 155-175, 2013.
6. L. U. Wahlberg, G. Lind, P. M. Almqvist et al., "Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery, " Journal of Neurosurgery, vol. 117, no. 2, pp. 340-347, 2012.
7. J. M. Eriksdotter, A. Nordberg, K. Amberla et al., "Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimers disease, " Dementia and Geriatric Cognitive Disorders, vol. 9, no. 5, pp. 246-257, 1998.
8. L. A. Quina, W. Pak, J. Lanier et al., "Brn3a-expressing retinal ganglion cells project specifically to thalamocortical and collicular visual pathways, " The Journal of Neuroscience, vol. 25, no. 50, pp. 11595-11604, 2005.
9. M. Coassin, A. Lambiase, V. Sposato, A. Micera, S. Bonini, and L. Aloe, "Retinal p75 and bax overexpression is associated with retinal ganglion cells apoptosis in a rat model of glaucoma, " Graefes Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 12, pp. 1743-1749, 2008.
10. A. S. Felix, R. P. Edwards, R. A. Stone et al., "Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients, " The British Journal of Cancer, vol. 106, no. 12, pp. 2004-2009, 2012.
11. B. P. Madakashira, D. A. Kobrinski, A. D. Hancher et al., "Frs2α enhances fibroblast growth factor-mediated survival and differentiation in lens development, " Development, vol. 139, no. 24, pp. 4601-4612, 2012.
12. P. M. Costa, A. L. Cardoso, L. F. P. de almeida, J. N. Bruce, P. Canoll, and M. C. P. de lima, "PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma, " HumanMolecular Genetics, vol. 21, no. 23, Article ID dds358, pp. 5118-5130, 2012.
13. R. Getachew, M. L. Ballinger, M. L. Burch et al., "PDGF β-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL, " Endocrinology, vol. 151, no. 9, pp. 4356-4367, 2010.
14. A. Lantero, M. Tramullas, A. Diaz, and M. A. Hurle, "Transforming growth factor-β in normal nociceptive processing and pathological pain models, " Molecular Neurobiology, vol. 45, no. 1, pp. 76-86, 2012.
15. W. M. Cowan, "Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor, " Annual Review of Neuroscience, vol. 24, pp. 551-600, 2001.
16. C. Lanave, A. M. Colangelo, C. Saccone, and L. Alberghina, "Molecular evolution of the neurotrophin family members and their Trk receptors, " Gene, vol. 394, no. 1-2, pp. 1-12, 2007.
17. R. Lee, P. Kermani, K. K. Teng, and B. L. Hempstead, "Regulation of cell survival by secreted proneurotrophins, " Science, vol. 294, no. 5548, pp. 1945-1948, 2001.
18. B. A. Tucker, M. Rahimtula, and K. M. Mearow, "Src and FAK are key early signalling intermediates required for neurite growth in NGF-responsive adult DRG neurons, " Cellular Signalling, vol. 20, no. 1, pp. 241-257, 2008.
19. Z. Hu, M. Ulfendahl, and N. P. Olivius, "NGF stimulates extensive neurite outgrowth from implanted dorsal root ganglion neurons following transplantation into the adult rat inner ear, " Neurobiology of Disease, vol. 18, no. 1, pp. 184-192, 2005.
20. L. Xu, S. Zhou, G.-Y. Feng et al., "Neural stem cells enhance nerve regeneration after sciatic nerve injury in rats, " Molecular Neurobiology, vol. 46, no. 2, pp. 265-274, 2012.
21. D. J. Lomb, L. A. Desouza, J. L. Franklin, and R. S. Freeman, "Prolyl hydroxylase inhibitors depend on extracellular glucose and hypoxia-inducible factor (HIF)-2α to inhibit cell death caused by nerve growth factor (NGF) deprivation: evidence that HIF-2α has a role in NGF-promoted survival of sympathetic neurons, "Molecular Pharmacology, vol. 75, no. 5, pp. 1198-1209, 2009.
22. M. H. Tuszynski and A. Blesch, "Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimers disease, " Progress in Brain Research, vol. 146, pp. 441-449, 2004.
23. A. Cattaneo and P. Calissano, "Nerve growth factor and Alzheimers disease: new facts for an old hypothesis., "Molecular neurobiology, vol. 46, no. 3, pp. 588-604, 2012.
24. K. Biernacki, J. P. Antel, M. Blain, S. Narayanan, D. L. Arnold, and A. Prat, "Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis, " Archives of Neurology, vol. 62, no. 4, pp. 563-568, 2005.
25. J. E. McGeary, V. Gurel, V. S. Knopik, J. Spaulding, and J. McMichael, "Effects of nerve growth factor (NGF), fluoxetine, and amitriptyline on gene expression profiles in rat brain, " Neuropeptides, vol. 45, no. 5, pp. 317-322, 2011.
26. K. B. Nelson, J. K. Grether, L. A. Croen et al., "Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation, " Annals of Neurology, vol. 49, no. 5, pp. 597-606, 2001.
27. W. Zheng, H. Wang, Z. Zeng et al., "The possible role of the Akt signaling pathway in schizophrenia, " Brain Research, vol. 1470, pp. 145-158, 2012.
28. R. Levi-Montalcini, "The nerve growth factor and the neuroscience chess board, " Progress in brain research, vol. 146, pp. 525-527, 2004.
29. G. N. Chaldakov, I. S. Stankulov, M. Fiore, P. I. Ghenev, and L. Aloe, "Nerve growth factor levels andmast cell distribution in human coronary atherosclerosis, " Atherosclerosis, vol. 159, no. 1, pp. 57-66, 2001.
30. L. Manni, V. Nikolova, D. Vyagova, G. N. Chaldakov, and L. Aloe, "Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes, " International Journal of Cardiology, vol. 102, no. 1, pp. 169-171, 2005.
31. H. T. Cheng, J. R. Dauch, J. M. Hayes, B. M. Yanik, and E. L. Feldman, "Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes, " Neurobiology of Disease, vol. 45, no. 1, pp. 280-287, 2012.
32. G. N. Chaldakov, M. Fiore, I. S. Stankulov et al., "Neurotrophin presence in human coronary atherosclerosis andmetabolic syndrome: a role for NGF and BDNF in cardiovascular disease?" Progress in Brain Research, vol. 146, pp. 279-289, 2004.
33. R. Romon, E. Adriaenssens, C. Lagadec, E. Germain, H. Hondermarck, and X. le Bourhis, "Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways, " Molecular Cancer, vol. 9, article 157, 2010.
34. D. Deponti, R. Buono, G. Catanzaro et al., "The low-affinity receptor for neurotrophins p75 NTR plays a key role for satellite cell function in muscle repair acting via RhoA, " Molecular Biology of the Cell, vol. 20, no. 16, pp. 3620-3627, 2009.
35. Y. Bai, P. Dergham, H. Nedev et al., "Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism, "The Journal of Biological Chemistry, vol. 285, no. 50, pp. 39392-39400, 2010.
36. S. Verbeke, S. Meignan, C. Lagadec et al., "Overexpression of p75NTR increases survival of breast cancer cells through p21waf1, " Cellular Signalling, vol. 22, no. 12, pp. 1864-1873, 2010.
37. K.-F. Lee, A. M. Davies, and R. Jaenisch, "p75-deficient embryonic dorsal root sensory and neonatal sympathetic neurons display a decreased sensitivity to NGF, " Development, vol. 120, no. 4, pp. 1027-1033, 1994.
38. M. Bothwell, "Tissue localization of nerve growth factor and nerve growth factor receptors, " Current Topics in Microbiology and Immunology, vol. 165, pp. 55-70, 1991.
39. G. Niewiadomska, A. Mietelska-Porowska, and M. Mazurkiewicz, "The cholinergic system, nerve growth factor and the cytoskeleton, " Behavioural Brain Research, vol. 221, no. 2, pp. 515-526, 2011.
40. S. K. Mahata, M. Mahata, H. Wu, R. J. Parmer, and D. T. OConnor, "Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin a biosynthesis, " Neuroscience, vol. 88, no. 2, pp. 405-424, 1999.
41. W.-H. Zheng, S. Kar, and R. Quirion, "Insulin-like growth factor-1-induced phosphorylation of transcription factor FKHRL1 is mediated by phosphatidylinositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth factor-1-induced survival of cultured hippocampal neurons, " Molecular Pharmacology, vol. 62, no. 2, pp. 225-233, 2002.
42. Y.-P. Xia, R.-L. Dai, Y.-N. Li et al., "The protective effect of sonic hedgehog is mediated by the phosphoinositide corrected 3-kinase/AKT/Bcl-2 pathway in cultured rat astrocytes under oxidative stress, " Neuroscience, vol. 209, pp. 1-11, 2012.
43. H. Wang, X. Zhou, J. Huang et al., "The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosteroneinduced cell death in PC12 cells, " Psychopharmacology, vol. 228, no. 1, pp. 129-141, 2013.
44. W.-H. Zheng, S. Kar, and R. Quirion, "FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling, " Journal of Neurochemistry, vol. 80, no. 6, pp. 1049-1061, 2002.
45. W.-H. Zheng and R. Quirion, "Glutamate acting on N-methyl-D-aspartate receptors attenuates insulin-like growth factor-1 receptor tyrosine phosphorylation and its survival signaling properties in rat hippocampal neurons, " The Journal of Biological Chemistry, vol. 284, no. 2, pp. 855-861, 2009.
46. W. Huang, G. Li, J. Qiu, P. Gonzalez, and P. Challa, "Protective effects of resveratrol in experimental retinal detachment, " PLoS ONE, vol. 8, no. 9, Article ID e75735, 2013.
47. W. Chen, J. L. Martindale, N. J. Holbrook, and Y. Liu, "Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc, "Molecular and Cellular Biology, vol. 18, no. 9, pp. 5178-5188, 1998.
48. Z. Wang, Y. Liu, M. Takahashi et al., "N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 1, pp. 312-317, 2013.
49. Y.-T. Oh, P. Yue, W. Zhou et al., "Oncogenic Ras and BRaf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling, " The Journal of Biological Chemistry, vol. 287, no. 1, pp. 257-267, 2012.
50. H.-C. Cheng, H.-M. Shih, and Y. Chern, "Essential role of cAMP-response element-binding protein activation by A2A adenosine receptors in rescuing the nerve growth factorinduced neurite outgrowth impaired by blockage of the MAPK cascade, "The Journal of Biological Chemistry, vol. 277, no. 37, pp. 33930-33942, 2002.
51. C. Cabeza, A. Figueroa, O. M. Lazo et al., "Cholinergic abnormalities, endosomal alterations and up-regulation of nerve growth factor signaling in Niemann-Pick type C disease, " Molecular Neurodegeneration, vol. 7, article 11, 2012.
52. H. S. Je, F. Yang, Y. Ji, G. Nagappan, B. L. Hempstead, and B. Lu, "Role of pro-brain-derived neurotrophic factor (proBDNF) to mature BDNF conversion in activity-dependent competition at developing neuromuscular synapses, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 39, pp. 15924-15929, 2012.
53. A. W. Harrington, J. Y. Kim, and S. O. Yoon, "Activation of Rac GTPase by p75 is necessary for c-jun N-terminal kinasemediated apoptosis, " Journal of Neuroscience, vol. 22, no. 1, pp. 156-166, 2002.
54. J. Liu and A. Lin, "Role of JNK activation in apoptosis: a doubleedged sword, " Cell Research, vol. 15, no. 1, pp. 36-42, 2005.
55. M. Hamanoue, G. Middleton, S. Wyatt, E. Jaffray, R. T. Hay, and A. M. Davies, "p75-Mediated NF-κB activation enhances the survival response of developing sensory neurons to nerve growth factor, "Molecular and Cellular Neurosciences, vol. 14, no. 1, pp. 28-40, 1999.
56. P. A. Barker and E. M. Shooter, "Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 cells, " Neuron, vol. 13, no. 1, pp. 203-215, 1994.
57. P. A. Hantzopoulos, C. Suri, D. J. Glass, M. P. Goldfarb, and G. D. Yancopoulos, "The low affinity NGF receptor, p75, can collaborate with each of the Trks to potentiate functional responses to the neurotrophins, " Neuron, vol. 13, no. 1, pp. 187-201, 1994.
58. D. Mahadeo, L. Kaplan, M. V. Chao, and B. L. Hempstead, "High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multisubunit polypeptide receptors, " Journal of Biological Chemistry, vol. 269, no. 9, pp. 6884-6891, 1994.
59. T. Wehrman, X. He, B. Raab, A. Dukipatti, H. Blau, and K. C. Garcia, "Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors, " Neuron, vol. 53, no. 1, pp. 25-38, 2007.
60. S. L. Mansberger, B. A. Hughes, M. O. Gordon et al., "Comparison of initial intraocular pressure response with topical β-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the ocular hypertension treatment study, " Archives of Ophthalmology, vol. 125, no. 4, pp. 454-459, 2007.
61. N. Comes and T. Borras, "Individual molecular response to elevated intraocular pressure in perfused postmortem human eyes, " Physiological Genomics, vol. 38, no. 2, pp. 205-225, 2009.
62. B. J. Frankfort, A. Kareem Khan, D. Y. Tse et al., "Elevated intraocular pressure causes inner retinal dysfunction before cell loss in a mouse model of experimental glaucoma, " Investigative Ophthalmology & Visual Science, vol. 54, no. 1, pp. 762-770, 2013.
63. S.-P. Cai, P. Muhemaiti, Y. Yin et al., "A novel MYOC heterzygous mutation identified in a Chinese Uygur pedigree with primary open-angle glaucoma, " Molecular Vision, vol. 18, pp. 1944-1951, 2012.
64. V. Mendoza-Reinoso, T. S. Patil, M. L. Guevara-Fujita et al., "Novel and known MYOC exon 3 mutations in an admixed Peruvian primary open-angle glaucoma population, "Molecular Vision, vol. 18, pp. 2067-2075, 2012.
65. B. J. Fan and J. L. Wiggs, "Glaucoma: genes, phenotypes, and new directions for therapy, "The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3064-3072, 2010.
66. J. B. Jonas, A. Bergua, P. Schmitz-Valckenberg, K. I. Papastathopoulos, andW. M. Budde, "Ranking of optic disc variables for detection of glaucomatous optic nerve damage, " Investigative Ophthalmology and Visual Science, vol. 41, no. 7, pp. 1764-1773, 2000.
67. C. T. FuandD. W. Sretavan, "Ectopic vesicular glutamate release at the optic nerve head and axon loss in mouse experimental glaucoma, " The Journal of Neuroscience, vol. 32, no. 45, pp. 15859-15876, 2012.
68. B. Junglas, S. Kuespert, A. A. Seleem et al., "Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork, " The American Journal of Pathology, vol. 180, no. 6, pp. 2386-2403, 2012.
69. J. T. Wang, Z. A. Medress, andB. A. Barres, "Axondegeneration: molecularmechanisms of a self-destruction pathway, " Journal of Cell Biology, vol. 196, no. 1, pp. 7-18, 2012.
70. Y. Lei, N. Garrahan, B. Hermann et al., "Topography of neuron loss in the retinal ganglion cell layer in human glaucoma, " British Journal of Ophthalmology, vol. 93, no. 12, pp. 1676-1679, 2009.
71. C. V. Borlongan, "Recent preclinical evidence advancing cell therapy for Alzheimer's disease, " Experimental Neurology, vol. 237, no. 1, pp. 142-146, 2012.
72. L.-Y. Li, J.-T. Li, Q.-Y. Wu et al., "Transplantation of NGFgene-modified bone marrow stromal cells into a rat model of Alzheimer disease, " Journal of Molecular Neuroscience, vol. 34, no. 2, pp. 157-163, 2008.
73. N. Agarwal, R. Agarwal, D. M. Kumar et al., "Comparison of expression profile of neurotrophins and their receptors in primary and transformed rat retinal ganglion cells, " Molecular Vision, vol. 13, pp. 1311-1318, 2007.
74. S. Cohen-Cory and B. Lom, "Neurotrophic regulation of retinal ganglion cell synaptic connectivity: fromaxons and dendrites to synapses, " International Journal of Developmental Biology, vol. 48, no. 8-9, pp. 947-956, 2004.
75. V. Sposato, V. Parisi, L. Manni et al., "Glaucoma alters the expression of NGF and NGF receptors in visual cortex and geniculate nucleus of rats: effect of eye NGF application, " Vision Research, vol. 49, no. 1, pp. 54-63, 2009.
76. M. Rudzinski, T.-P. Wong, and H. U. Saragovi, "Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension, " Journal of Neurobiology, vol. 58, no. 3, pp. 341-354, 2004.
77. S. Capsoni, C. Tiveron, D. Vignone, G. Amato, and A. Cattaneo, "Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 27, pp. 12299-12304, 2010.
78. S. Capsoni, C. Tiveron, G. Amato, D. Vignone, and A. Cattaneo, "Peripheral neutralization of nerve growth factor induces immunosympathectomy and central neurodegeneration in transgenic mice, " Journal of Alzheimers Disease, vol. 20, no. 2, pp. 527-546, 2010.
79. J. M. Conner, K. M. Franks, A. K. Titterness et al., "NGF is essential for hippocampal plasticity and learning, " The Journal of Neuroscience, vol. 29, no. 35, pp. 10883-10889, 2009.
80. G. Carmignoto, R. Canella, P. Candeo, M. C. Comelli, and L. Maffei, "Effects of nerve growth factor on neuronal plasticity of the kitten visual cortex, " The Journal of Physiology, vol. 464, pp. 343-360, 1993.
81. S. T. Lockhart, J. N. Mead, J. M. Pisano, J. D. Slonimsky, and S. J. Birren, "Nerve growth factor collaborateswithmyocyte-derived factors to promote development of presynaptic sites in cultured sympathetic neurons, " Journal ofNeurobiology, vol. 42, no. 4, pp. 460-476, 2000.
82. Y. Liu, K. F. Meiri, M. S. Cynader, and Q. Gu, "Nerve growth factor induced modification of presynaptic elements in adult visual cortex in vivo, " Brain Research, vol. 732, no. 1-2, pp. 36-42, 1996.
83. K. K. McDonald, K. Abramson, M. A. Beltran et al., "Myocilin and optineurin coding variants inHispanics ofMexican descent with POAG, " Journal ofHuman Genetics, vol. 55, no. 10, pp. 697-700, 2010.
84. T. Rezaie, A. Child, R. Hitchings et al., "Adult-onset primary open-angle glaucoma caused by mutations in optineurin, " Science, vol. 295, no. 5557, pp. 1077-1079, 2002.
85. B.-C. Park, M. Tibudan, M. Samaraweera, X. Shen, and B. Y. J. T. Yue, "Interaction between two glaucoma genes, optineurin and myocilin, " Genes to Cells, vol. 12, no. 8, pp. 969-979, 2007.
86. T. Koga, X. Shen, J.-S. Park et al., "Differential effects ofmyocilin and optineurin, two glaucoma genes, on neurite outgrowth, " The American Journal of Pathology, vol. 176, no. 1, pp. 343-352, 2010.
87. W. C. Skarnes, B. Rosen, A. P. West et al., "A conditional knockout resource for the genome-wide study of mouse gene function, " Nature, vol. 474, no. 7351, pp. 337-342, 2011.
88. B. S. Kim, O. V. Savinova, M. V. Reedy et al., "Targeted disruption of the myocilin gene (Myoc) suggests that human glaucoma-causing mutations are gain of function, " Molecular and Cellular Biology, vol. 21, no. 22, pp. 7707-7713, 2001.
89. J. Kohn, R. S. Aloyz, J. G. Toma, M. Haak-Frendscho, and F. D. Miller, "Functionally antagonistic interactions between the TrkA and p75 neurotrophin receptors regulate sympathetic neuron growth and target innervation, " Journal of Neuroscience, vol. 19, no. 13, pp. 5393-5408, 1999.
90. S. O. Yoon, P. Casaccia-Bonnefil, B. Carter, and M. V. Chao, "Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival, " The Journal of Neuroscience, vol. 18, no. 9, pp. 3273-3281, 1998.
91. S. X. Bamji, M. Majdan, C. D. Pozniak et al., "The p75 neurotrophin receptormediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death, " The Journal of Cell Biology, vol. 140, no. 4, pp. 911-923, 1998.
92. Z. Shi, E. Birman, and H. U. Saragovi, "Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo, " Developmental Neurobiology, vol. 67, no. 7, pp. 884-894, 2007.
93. F. Lebrun-Julien, B. Morquette, A. Douillette, H. U. Saragovi, andA. Di Polo, "Inhibition of p75NTR in glia potentiatesTrkAmediated survival of injured retinal ganglion cells, " Molecular and Cellular Neuroscience, vol. 40, no. 4, pp. 410-420, 2009.
94. B. D. Carter and G. R. Lewint, "Neurotrophins live or let die: does p75(NTR) decide?" Neuron, vol. 18, no. 2, pp. 187-190, 1997.
95. J. M. Cosgaya, J. R. Chan, and E. M. Shooter, "The neurotrophin receptor p75NTR as a positive modulator of myelination, " Science, vol. 298, no. 5596, pp. 1245-1248, 2002.
96. S. Capsoni, G. Ugolini, A. Comparini, F. Ruberti, N. Berardi, and A. Cattaneo, "Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6826-6831, 2000.
97. L. Olson, "NGF and the treatment of Alzheimers disease, " Experimental Neurology, vol. 124, no. 1, pp. 5-15, 1993.
98. V. Colafrancesco, V. Parisi, V. Sposato et al., "Ocular application of nerve growth factor protects degenerating retinal ganglion cells in a rat model of glaucoma, " Journal of Glaucoma, vol. 20, no. 2, pp. 100-108, 2011.
99. A. Lambiase, L. Aloe, M. Centofanti et al., "Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 32, pp. 13469-13474, 2009.
100. K. Akassoglou, "Nerve growth factor-independent neuronal survival: a role for NO donors, " Molecular Pharmacology, vol. 68, no. 4, pp. 952-955, 2005.
101. M. H. Tuszynski, L. Thal, M. Pay et al., "A phase 1 clinical trial of nerve growth factor gene therapy forAlzheimer disease, " Nature Medicine, vol. 11, no. 5, pp. 551-555, 2005.
102. S. M. Massa, Y. Xie, and F. M. Longo, "Alzheimers therapeutics: neurotrophin domain small molecule mimetics, " Journal of Molecular Neuroscience, vol. 20, no. 3, pp. 323-326, 2003.
103. K. Lee, E. A. Silva, and D. J. Mooney, "Growth factor deliverybased tissue engineering: general approaches and a review of recent developments, " Journal of the Royal Society Interface, vol. 8, no. 55, pp. 153-170, 2011.